

10829139s3

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 6 SEP 21 CA/CAplus fields enhanced with simultaneous left and right truncation  
NEWS 7 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced  
NEWS 8 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates  
NEWS 9 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine  
NEWS 10 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme  
NEWS 11 OCT 19 LOGOFF HOLD duration extended to 120 minutes  
NEWS 12 OCT 19 E-mail format enhanced  
NEWS 13 OCT 23 Option to turn off MARPAT highlighting enhancements available  
NEWS 14 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases  
NEWS 15 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded  
NEWS 16 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 17 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 18 NOV 10 CA/CAplus F-Term thesaurus enhanced  
NEWS 19 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available  
NEWS 20 NOV 20 CAS Registry Number crossover limit increased to 300,000 in additional databases  
NEWS 21 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased to 50,000  
NEWS 22 DEC 01 CAS REGISTRY updated with new ambiguity codes  
NEWS 23 DEC 11 CAS REGISTRY chemical nomenclature enhanced  
NEWS 24 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated  
NEWS 25 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and functionality  
NEWS 26 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role  
NEWS 27 DEC 18 CA/CAplus patent kind codes updated  
NEWS 28 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased to 50,000  
NEWS 29 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 30 DEC 27 CA/CAplus enhanced with more pre-1907 records  
  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

10829139s3

NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:25:29 ON 04 JAN 2007

=> fil reg  
COST IN U.S. DOLLARS . . . . . SINCE FILE . . . . . TOTAL  
FULL ESTIMATED COST . . . . . ENTRY . . . . . SESSION  
0.84 . . . . . 0.84

FILE 'REGISTRY' ENTERED AT 10:27:51 ON 04 JAN 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 JAN 2007 HIGHEST RN 916687-76-8  
DICTIONARY FILE UPDATES: 3 JAN 2007 HIGHEST RN 916687-76-8

New CAS Information Use Policies. enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

=> Uploading C:\Program Files\Stnexp\Queries\10829139sbroad.str

10829139s3



chain nodes :

10 12

ring nodes :

1 2 3 4 5 6 7 8 9 11 13 14 15 16 17 18 19 20 24 25 26 27 28  
29

chain bonds :

7-11 8-10 9-12 12-24

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 11-13 11-16 13-14 14-15 15-16  
15-17 16-20 17-18 18-19 19-20 24-25 24-29 25-26 26-27 27-28 28-29

exact/norm bonds :

4-5 4-7 5-9 7-8 7-11 8-9 8-10 9-12 11-13 11-16 12-24 13-14 14-15 15-16  
15-17 16-20 17-18 18-19 19-20 24-25 24-29 25-26 26-27 27-28 28-29

normalized bonds :

1-2 1-6 2-3 3-4 5-6

G1:C,O

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10829139s3



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 10:28:30 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01  
  
FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 4 TO 200  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full  
FULL SEARCH INITIATED 10:28:35 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 40 TO ITERATE

100.0% PROCESSED 40 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.94

FILE 'HCAPLUS' ENTERED AT 10:28:39 ON 04 JAN 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10829139s3

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Jan 2007 VOL 146 ISS 2  
FILE LAST UPDATED: 3 Jan 2007 (20070103/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
L4 2 L3

=> d ed ibib abs hitstr 1-2


10829139s3

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ED Entered STN: 28 May 2004  
 ACCESSION NUMBER: 2004:433773 HCAPLUS  
 DOCUMENT NUMBER: 140:423586  
 TITLE: Preparation of dihydroindolones as tyrosine kinase inhibitors for the treatment of disease  
 INVENTOR(S): Andrews, Steven W.; Garst, Michael E.; Guo, Xialing; Hebert, Jonathan J.; Malone, Thomas; Wurster, Julie A.; Hull, Clarence Eugene  
 PATENT ASSIGNEE(S): Allergan, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont. of U.S. Ser. No. 306,975, abandoned.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102509	A1	20040527	US 2003-389416	20030313
US 6747025	B2	20040608		
CA 2507780	A1	20040617	CA 2003-2507780	20031119
WO 2004050621	A2	20040617	WO 2003-US36988	20031119
WO 2004050621	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
AU 2003295658	A1	20040623	AU 2003-295658	20031119
GB 2410744	A	20050810	GB 2005-11267	20031119
GB 2410744	B	20060412		
BR 2003016744	A	20051018	BR 2003-16744	20031119
JP 2006512400	T	20060413	JP 2004-570761	20031119
US 2004198802	A1	20041007	US 2004-829139	20040420
PRIORITY APPLN. INFO.:			US 2002-306975	B1 20021127
			US 2002-307097	A 20021127
			US 2003-389416	A 20030313
			WO 2003-US36988	W 20031119

OTHER SOURCE(S): MARPAT 140:423586  
 GI


L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title compds. [I or II; X = O, C(R2)2; Y = [C(R2)2]c; A = NR2, absent; R1 = halo, OH, NO2, CN, etc.; R2 = H, alkyl, Ph, etc.; R = halo, (un)substituted hydrocarbyl; R3, R6 = H, (un)substituted hydrocarbyl; NR3R4 = (hetero)cyclic ring; R5, R6 = H, alkyl, aryl; a = 0-3; b = 0-3; c = 1-2] which are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, were prepared. Thus, reacting 4-morpholinaniline with 3-(hydroxymethylene)-1,3-dihydroindol-2-one (preparation given) in THF afforded 92% 3-[4-morpholinophenylamino]-methylene]-1,3-dihydroindol-2-one which showed IC50 of 260 nM against VEGFR2 kinase.


IT 663903-86-4P 663903-90-0P  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of dihydroindolones as tyrosine kinase inhibitors for treatment of disease)

RN 663903-86-4 HCAPLUS  
 CN 2H-Indol-2-one, 1,3-dihydro-3-(1(3H)-isobenzofuranylidene)-1-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 663903-90-0 HCAPLUS

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 2H-Indol-2-one, 3-(5-(dimethylamino)-1(3H)-isobenzofuranylidene)-1,3-dihydro-1-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



IT 663903-91-1P  
 RI: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of dihydroindolones as tyrosine kinase inhibitors for treatment of disease)  
 RN 663903-91-1 HCAPLUS  
 CN 2H-Indol-2-one, 5-chloro-3-[5-(dimethylamino)-1(3H)-isobenzofuranylidene]-1,3-dihydro-1-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 04 Mar 2004  
 ACCESSION NUMBER: 2004:176559 HCAPLUS  
 DOCUMENT NUMBER: 140:210752  
 TITLE: Dihydroindolone compound tyrosine kinase inhibitors for the treatment of disease  
 INVENTOR(S): Andrews, Steven W.; Hebert, Jonathan J.  
 PATENT ASSIGNEE(S): Allergan, Inc., USA  
 SOURCE: U.S., 14 pp.  
 CODEN: USXXAM

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6699863	B1	20040302	US 2002-307097	20021127
CA 2507780	A1	20040617	CA 2003-2507780	20031119
WO 2004050621	A2	20040617	WO 2003-US36988	20031119
WO 2004050621	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
AU 2003295658	A1	20040623	AU 2003-295658	20031119
GB 2410744	A	20050810	GB 2005-11267	20031119
GB 2410744	B	20060412		
BR 2003016744	A	20051018	BR 2003-16744	20031119
JP 2006512400	T	20060413	JP 2004-570761	20031119
PRIORITY APPLN. INFO.:			US 2002-306975	A 20021127
			US 2002-307097	A 20021127
			US 2003-389416	A 20030313
			WO 2003-US36988	W 20031119

OTHER SOURCE(S): MARPAT 140:210752  
 AB The invention discloses organic mol., especially dihydroindolone derivs. (preparation

described) capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.


IT 663903-86-4P 663903-90-0P  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(dihydroindolone derivative tyrosine kinase inhibitors for treatment of disease)


RN 663903-86-4 HCAPLUS  
 CN 2H-Indol-2-one, 1,3-dihydro-3-(1(3H)-isobenzofuranylidene)-1-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)

10829139s3


L4 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 663903-90-0 HCPLUS  
CN 2H-Indol-2-one, 3-[5-(dimethylamino)-1(3H)-isobenzofuranylidene]-1,3-dihydro-1-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



IT 663903-91-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(dihydroindole derivative tyrosine kinase inhibitors for treatment  
of  
disease)  
RN 663903-91-1 HCPLUS  
CN 2H-Indol-2-one,  
5-chloro-3-[5-(dimethylamino)-1(3H)-isobenzofuranylidene]-1,3-dihydro-1-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

10829139s3

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	13.14	186.08
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 10:29:07 ON 04 JAN 2007